Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO.O), opens new tab jumped nearly 16% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the ...
Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia ...
Agios expects Aqvesme to be available in late January 2026 following full REMS implementation. H.C. Wainwright updated its model to reflect a first-quarter 2026 commercial launch and increased the ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Agios Pharmaceuticals, Inc.’s (NASDAQ: AGIO) Aqvesme (mitapivat), an oral pyruvate kinase (PK) activator, for anemia in adults with ...
The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a ...
Dec 24 (Reuters) - Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a ...
What is the current share price of Agios Pharmaceuticals (AGIO)? Agios Pharmaceuticals's (AGIO) current share price is $27.27. This constitutes a price movement of 0.55% when compared to the share ...
CAMBRIDGE - The U.S. Food and Drug Administration (FDA) has not issued a decision on Agios Pharmaceuticals’ (NASDAQ:AGIO) supplemental New Drug Application (sNDA) for mitapivat by its expected ...
World No. 1 Aryna Sabalenka is back in training for the 2026 season after a rewarding 2025. She shared glimpses of her fitness routine and diet on Instagram, captioned 'Train, chill, eat, repeat.' Her ...
Shares of Agios Pharmaceuticals (AGIO) bounced back with a ~10% rise on Thursday as Leerink Partners upgraded the biotech, arguing that the stock, which dropped over 50% in the previous session in ...
Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026. The trial was designed with two primary endpoints, and it hit ...
Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026. Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results